Beta Bionics, Inc. (BBNX)
Nasdaq · Healthcare · Medical Devices
$18.95−0.05%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.0B
- 52-week range
- $8.80 – $32.71
- 52-week change
- −13.62%
- EPS (trailing)
- −$1.64
- Analyst rating
- 1.7 Buy
- Next earnings
- Oct 27, 2026
Fiscal year to Dec 2025
- Revenue
- $100M (+53.94%)
- Net income
- −$73.2M
- Operating margin
- −71.5%
- Diluted EPS
- −$1.81
- Free cash flow
- −$56.2M
From the company’s annual report on SEC EDGAR.
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Headquarters: Irvine, United States · 420 employees · betabionics.com